News & Events

Category: News

Vivli releases major update of the platform

Version 2.0 of the Vivli platform has been released and is available to users.

“The improvements to the underlying infrastructure of Vivli should have major benefits to our users,” said Julie Wood, Vivli Director of Strategy and Operations. “We have updated Vivli to take advantage of many of the newer benefits of Microsoft Azure, including the option for users to have larger, more optimized research environments as well as the ability to process and analyze up to 1T of data.”

The release includes several new features:

  • In the research environment, ability to process and analyze much larger data files (up to 1T of data)
  • Option for researchers to choose for larger, optimized research environments to conduct their analysis
  • Ability for researchers to add R packages from CRAN not already included as standard
  • Updated suite of tools and software as standard in the research environment
  • Metadata available about Vivli studies in Google Dataset Search
  • Ability for supporting documents to be made available to researchers searching for studies

d-wise and Vivli Announce Partnership to Offer Anonymization Services and Software for Institutions and Researchers Contributing to Clinical Research Data Sharing

Leading Life Science IT services and software provider, d-wise, an Instem Company, and Vivli are pleased to announce a partnership aimed at providing easily accessible anonymization services and software to leading institutions (biopharmaceutical companies, academic institutions of higher learning) as well as individual researchers planning to share clinical research data on Vivli’s global data sharing platform.

Vivli, is an independent, non-profit organization focused on sharing individual participant-level data from completed clinical trials to serve the international research community. Their platform enables global collaboration and access to data to accelerate scientific insights. Data contributors wishing to share clinical trial data have a responsibility to ensure that trial participants cannot be personally identified. Depending on the size and bandwidth of the organization sharing the data, they may not have a standard method or process for data anonymization in place.

“There are several reasons why sharing clinical research data is important, from global collaboration to moral obligations,” shared Kristin McDougall, Director of Transparency at d-wise. “The go-to partner for many of our clients who proactively share their data is Vivli. d-wise is thrilled to expand into a direct partnership with Vivli so our anonymization software and services can be adopted by a broad, diverse community of stakeholders with a shared goal of advancing human health through the insights and discoveries gained by sharing and analyzing data.”

“We are delighted to partner with d-wise and have them become part of our data sharing community,” said Rebecca Li, Vivli Executive Director. “We believe that together we make it easier for the entire data sharing community to securely share the data from completed clinical trials to advance human health and gain new insights for scientific discovery.”

d-wise offers outsourced anonymization services utilizing industry-leading anonymization software, Blur, allowing sponsors to overcome this hurdle and responsibly share trial data on the Vivli platform while protecting patient data and retaining as much data utility as possible. This empowers pharmaceutical companies to share on a global scale without impacting internal workflows.

This partnership permits both d-wise and Vivli to continue working toward a shared mission to accelerate improvements in human health and wellbeing.

For more information, visit our websites.

d-wise.com

vivli.org

Vivli Executive Director Dr. Rebecca Li to speak at Ropes & Gray and Mass Insight Global Partnerships – a Data Science Webinar

Ropes & Gray and Mass Insight Global Partnerships will be featuring Vivli’s Executive Director, Dr. Rebecca Li, on their upcoming webinar, “Accelerating Next Generation Developments in Cancer Care: A Collaborative Agenda for Data Innovations and Policy.”

Ropes & Gray and Mass Insight Global Partnerships aim to highlight the impact data sharing has on scientific developments, specifically oncology clinical trial recruitment. The webinar will provide valuable insight into the role of data innovations on clinical research and cancer care.

This webinar will take place Wednesday, September 22 12:00-1:30 pm (4:00-5:30 pm GMT).

To learn more about Dr. Li’s presentation and RSVP for the event reach out to RGEvents@ropesgray.com.

Breast cancer research and data sharing – an interview with Dr. Ashley Hopkins

Vivli board member and Duke University Professor, Eric Perakslis, met with Dr. Ashley Hopkins of Flinders University to discuss the importance of his team’s research to help provide information to breast cancer patients and their doctors as to how they may react to certain medications.

Dr. Hopkins has used the Vivli platform to request data for research questions and recently published “Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib,” in Elsevier.

You can watch the entire conversation here or below.

Advancing the treatment of Crohn’s Disease through data sharing— An interview with Dr. Neeraj Narula

Vivli co-founder and UCSF professor Dr. Ida Sim had the opportunity to interview Dr. Neeraj Narula from McMaster University to discuss the value of clinical trials, data sharing, and what we’ve learned about advances in the treatment of Crohn’s Disease.

Dr. Narula has used the Vivli platform to request data for a number of research questions and recently published, “Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD),” in Gut.

You can watch the entire conversation here or below:

NIAID to list its studies on the Vivli platform

Vivli extends a warm welcome to our newest partner platform as a member, the NIAID Clinical Trials Data Repository, AccessClinicalData@NIAID.

“We are delighted to include AccessClinicalData@NIAID studies on the Vivli platform,” said Rebecca Li, Vivli Executive Director. “By making these valuable studies available for searching on Vivli, AccessClinicalData@NIAID is helping to ensure that researchers can find and access these important studies. It will help drive scientific discovery through data sharing to advance human health.”

NIAID Clinical Trials Data Repository, AccessClinicalData@NIAID, is an NIAID cloud-based, secure data platform that enables sharing of and access to anonymized individual, patient level clinical data sets from NIAID sponsored clinical trials to harness the power of data to generate new knowledge to understand, treat, and prevent COVID-19 and other infectious diseases.

For more information about how AccessClinicalData@NIAID shares its data on Vivli, please visit their member page. For additional information about Vivli membership, learn more here.

Advancing Management of Rheumatoid Arthritis — A conversation with researchers about the impact of their research

Vivli Board Member Dr. Stewart recently connected with researchers Prof. José António P. Da Silva and Dr. Ricardo J.O. Ferreira from the University of Coimbra to discuss the value of clinical trials, data sharing and specifically what we’ve learned about advances in rheumatology.

Dr. Ferreira and Prof. Da Silva used the Vivli platform to request data and recently published, “Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients,” in the Annals of the Rheumatic Diseases.

You can watch the entire conversation here or below:

Upcoming Vivli Webinar: Sharing Academic Clinical Research Data

Sharing Academic Clinical Research Data: Top Academic Administrators discuss why and how institutions can provide support

This webinar provides an introduction to why data from academic clinical research should be shared and is aimed at academic trial teams and staff. The panelists will take part in a free-flowing conversation and Q&A to share their experiences and perspectives in setting up an institutional framework to support sharing academic clinical research trial data. Join us for a conversation discussing current initiatives, challenges to data sharing, and how they are being overcome at academic institutions.

The webinar will be held on June 18th at 9:00 am PT / 12:00 pm ET / 5:00 pm GMT.

Recording

Key topics to be covered:

  • The importance of sharing clinical research data
  • Creating an institutional framework for sharing data
  • Overcoming pain points to data sharing

Panelists include: 

Moderator: Ida Sim, Co-Founder, Vivli & Professor of Medicine, UCSF
Dan Ford, Vice Dean for Clinical Investigation, Johns Hopkins University
Susanna Naggie, Vice Dean for Clinical Research, Duke
Kim Serpico, Associate Director for IRB Operations, Harvard
Ara Tahmassian, Chief Research Compliance Officer, Harvard

 

Vivli awarded contract to improve access to Antimicrobial Resistance Surveillance data

Vivli is pleased to announce that following on from the Wellcome Trust-Open Data Institute (ODI) AMR pilot, Wellcome has awarded a contract to Vivli which aims to improve the access and research use of antimicrobial resistance (AMR) surveillance data.

The Wellcome-ODI pilot project focused on gathering and openly publishing data on industry-sponsored human antimicrobial surveillance programs. Vivli will develop a plan to foster increased research using the surveillance data in collaboration with a Steering Committee of industry data contributors. The Steering Committee, as well as a Scientific Advisory Board, will help steward the project forward.

“Our hope is that the research project will further advance understanding in the medical community, global organizations such as the United Nations and the World Health Organisation, and wider society,” said Rebecca LI, Vivli Executive Director and lead for the project. “We would like to thank the Open Data Institute and all companies and stakeholders who took part in this initiative.”

Insight Enterprises, Vivli’s long-time partner, will undertake the technical development of the platform linked to this grant.

For any enquiries or questions about the new AMR register please fill out the contact form below:


    website is protected by reCAPTCHA v3

    Bill & Melinda Gates Foundation joins Vivli as a member

    The Foundation will support its grantees to cover the costs related to sharing clinical trial data.

    The Bill & Melinda Gates Foundation has joined Vivli as a member. The Foundation will support grantees to use the Vivli platform as an approved repository for their clinical trial data.

    “By depositing and sharing data via a stable and recognized platform, this ensures the grantee’s data will be able to be reused in a sustainable manner to further enhance scientific insights” said Rebecca Li, Vivli’s Executive Director

    “We believe that the tools and discoveries capable of helping us tackle the world’s most pressing challenges – from age-old diseases like malaria to newer threats like COVID-19 – can only be realized through innovative thinking and global collaboration. Access to data is critical for both of these things. This is why we are committed to increasing the impact of the research we fund so that it is findable, accessible, interoperable, and reusable through platforms like the one developed by Vivli,” Steven Kern, Deputy Director, Quantitative Sciences, The Bill & Melinda Gates Foundation.

    “We’re delighted to have the  Bill & Melinda Gates Foundation join as a member of Vivli and make this valuable data available. We welcome researchers interested in these important trials to visit the Vivli platform to access these datasets and potentially uncover new scientific discoveries,” said Li. “The Vivli platform is a secure and user-friendly platform to archive and share data from clinical trials, and we look forward to welcoming more funders to support their grantees to share their clinical research in the Vivli platform.”